
This AOP is licensed under a Creative Commons Attribution 4.0 International License.
Aop: 170
Title
Anti-dopaminergic activity leading to mammary adenomas and carcinomas in the SD rat
Short name
Graphical Representation
Point of Contact
Contributors
- Charles Wood
Status
Author status | OECD status | OECD project | SAAOP status |
---|---|---|---|
Under Development: Contributions and Comments Welcome | 1.29 | Under Development |
This AOP was last modified on June 04, 2021 13:38
Revision dates for related pages
Page | Revision Date/Time |
---|---|
Decreased, Dopaminergic activity | December 03, 2016 16:37 |
Increased, prolactin secretion | December 03, 2016 16:37 |
Increased, hyperplasia (mammary gland) | September 16, 2017 10:17 |
Increased, latency period | December 03, 2016 16:37 |
Increased, Adenomas/carcinomas (mammary) | September 16, 2017 10:17 |
Decreased, Dopaminergic activity leads to Increased, prolactin secretion | December 03, 2016 16:38 |
Increased, prolactin secretion leads to Increased, hyperplasia (mammary gland) | December 03, 2016 16:38 |
Increased, hyperplasia (mammary gland) leads to Increased, latency period | December 03, 2016 16:38 |
Increased, hyperplasia (mammary gland) leads to Increased, Adenomas/carcinomas (mammary) | December 03, 2016 16:38 |
Increased, latency period leads to Increased, Adenomas/carcinomas (mammary) | December 03, 2016 16:38 |
Haloperidol | November 29, 2016 18:42 |
Reserpine | November 29, 2016 18:42 |
Abstract
This putative adverse outcome pathway (AOP) outlines potential key events leading to a tumor outcome in standard carcinogenicity models. This information is based largely on modes of action described previously in cited literature sources and is intended as a resource template for AOP development and data organization. Presentation in this Wiki does not indicate EPA acceptance of a particular pathway for a given reference agent, only that the information has been proposed in some manner. In addition, this putative AOP relates to the model species indicated and does not directly address issues of human relevance.
AOP Development Strategy
Context
Strategy
Summary of the AOP
Events:
Molecular Initiating Events (MIE)
Key Events (KE)
Adverse Outcomes (AO)
Type | Event ID | Title | Short name |
---|
KE | 1083 | Decreased, Dopaminergic activity | Decreased, Dopaminergic activity |
KE | 1084 | Increased, prolactin secretion | Increased, prolactin secretion |
KE | 1085 | Increased, hyperplasia (mammary gland) | Increased, hyperplasia (mammary gland) |
KE | 1080 | Increased, latency period | Increased, latency period |
AO | 1079 | Increased, Adenomas/carcinomas (mammary) | Increased, Adenomas/carcinomas (mammary) |
Relationships Between Two Key Events (Including MIEs and AOs)
Title | Adjacency | Evidence | Quantitative Understanding |
---|
Decreased, Dopaminergic activity leads to Increased, prolactin secretion | non-adjacent | High | |
Increased, hyperplasia (mammary gland) leads to Increased, latency period | non-adjacent | Moderate | |
Increased, hyperplasia (mammary gland) leads to Increased, Adenomas/carcinomas (mammary) | non-adjacent | Moderate | |
Increased, latency period leads to Increased, Adenomas/carcinomas (mammary) | non-adjacent | Moderate |
Network View
Prototypical Stressors
Name |
---|
Haloperidol |
Reserpine |
Life Stage Applicability
Taxonomic Applicability
Term | Scientific Term | Evidence | Link |
---|---|---|---|
SD rat | Rattus norvegicus | High | NCBI |
Sex Applicability
Sex | Evidence |
---|---|
Female | High |
Overall Assessment of the AOP
Domain of Applicability
Essentiality of the Key Events
Evidence Assessment
Known Modulating Factors
Quantitative Understanding
Considerations for Potential Applications of the AOP (optional)
References
1. O'Connor, J. C., Davis, L. G., Frame, S. R., and Cook, J. C. (2000). Detection of dopaminergic modulators in a tier I screening battery for identifying endocrine-active compounds (EACs). Reproductive toxicology 14(3), 193-205.
2. Rudmann, D., Cardiff, R., Chouinard, L., Goodman, D., Kuttler, K., Marxfeld, H., Molinolo, A., Treumann, S., Yoshizawa, K., Inhand Mammary, Z. s. P., and Clitoral Gland Organ Working, G. (2012). Proliferative and nonproliferative lesions of the rat and mouse mammary, Zymbal's, preputial, and clitoral glands. Toxicologic pathology 40(6 Suppl), 7S-39S, 10.1177/0192623312454242.